Immunotherapy Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Immunotherapy Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Allergy & Immunology
Immunoglobulin rBet v1 G4-antibodies may modulate allergic rhinoconjunctivitis
February 8th, 2006
According to recent research from Sweden, immunoglobulin rBet v1 G4-antibodies may modulate allergic rhinoconjunctivitis. "In 1993 extremely high levels of birch-pollen were recorded in Stockholm, Sweden. This provided an opportunity to evaluate the effects of aeroallergen exposure (exp.) on the early immune response." A. Kihlstrom and colleagues, Huddinge University Hospital, wrote that the study was undertaken "to assess the influence of exp. to birch-pollen during pregnancy and infancy on the allergen-specific IgE- and IgG4-antibody (ab) response and the development of atopic disease in children." "A total of 970 children with...
Source: Immunotherapy Weekly (2006-02-08)
|
